Serina Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Serina Therapeutics, Inc. on September 9, 2025. The filing discloses the entry into a material definitive agreement involving a new financing instrument to support clinical operations.
Key Financial Metrics and Transaction Details
The Company entered into an unsecured convertible note with Gregory H. Bailey, M.D., a member of the Board of Directors. Key terms include:
- Total Principal Amount: Up to $20 million available in five tranches.
- Interest Rate: 10% annual interest, payable in cash starting on the first anniversary of initial funding.
- Maturity: Five years from the initial funding date.
- Conversion Price: $5.18 per share of Common Stock.
- Warrants: Issued equal to 100% of shares issuable upon conversion, with an exercise price of $5.44 per share.
- Seniority: Senior unsecured obligations, ranking pari passu with other unsecured indebtedness.
Material Changes and Milestone Triggers
Borrowings are tied to specific clinical and operational milestones. The Company may draw funds at its discretion, except where a deficiency in cash to cover projected costs for the next milestone triggers a mandatory draw. The tranches are structured as follows:
- Up to $5 million on or before September 30, 2025.
- Up to $2.5 million on or after December 15, 2025, upon enrollment of the first patient in the SER-252-1b registrational study.
- Up to $2.5 million upon enrollment of the second patient in the study.
- Up to $5 million on or after March 15, 2026, upon dosing of the last patient in Cohort 1.
- Up to $5 million on or after April 30, 2026, upon dosing of the first patient in Cohort 2.
The filing does not provide specific revenue, profit, cash flow, or existing debt figures for the reporting period.
Outlook, Risks, and Contingencies
Related Party Transaction: The lender is a Board designee appointed by Juvenescence Limited, the Company's largest shareholder. A Special Committee of independent directors approved the transaction.
Dilution Cap: The Company will not issue shares exceeding 19.99% of outstanding Common Stock (as of September 9, 2025) without stockholder approval. A proposal for such approval is scheduled for the 2025 annual meeting.
Liquidity Events: The note must be repaid in cash upon certain liquidity events or a change of control.
Default Provisions: An event of default triggers an additional 2% default interest.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet the mandatory draw requirement if cash is insufficient for projected costs.
- Confirm the status of patient enrollment for the SER-252-1b study to assess the timing of the $2.5 million tranches.
- Review the 2025 Annual Meeting proxy statement for the stockholder approval proposal regarding the 19.99% issuance cap.
- Assess the impact of the 10% cash interest payments on future liquidity once the first anniversary of funding is reached.
- Examine the full text of the Convertible Note (Exhibit 10.1) and Warrant Agreement (Exhibit 4.1) for detailed default and adjustment clauses.